Basilea have licensed pharmaceutical company Pfizer to produce and market their newest antifungal medication Cresemba (Isavuconazole). Unlike vFend (Voriconazole) experiments have show reduced tendency to cause side effects that include the visual or skin disorders. Skin disorders affect 21% fewer people compared with taking voriconazole and 43% fewer have eye disorders as a result of taking isavuconazole. Fewer patients discontinued therapy on isavuconazole (14% of 257 patients) compared with voriconazole (23% of 259 patients). However Cresemba is contraindicated in patients with familial short QT syndrome as it shortens QT interval
Isavuconazole is a newly developed intravenous (i.v.) and oral azole antifungal. It received marketing authorization in Europe for the treatment of adult patients with invasive aspergillosis and for the treatment of some adult patients with mucormycosis.
It is approved in the United States for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis.
Isavuconazole has orphan drug designation for the approved indications in Europe and the US. Isavuconazole is being marketed as Cresemba in Germany, Italy, the UK, France and Austria. In the US, the drug is marketed by Basilea's license partner Astellas Pharma US. Outside the US and the EU, isavuconazole is currently not approved for commercial use.